How to buy iBio shares

Own iBio shares in just a few minutes.

Updated

Fact checked

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

iBio, Inc is a biotechnology business with stocks listed in the US. iBio shares (IBIO) are listed on the NYSE MKT and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.

How to buy shares in iBio

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for iBio. Find the share by name or ticker symbol: IBIO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until iBio reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of iBio, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of iBio. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

iBio share price

Use our graph to track the performance of IBIO stocks over time.

iBio shares at a glance

Information last updated 2021-02-23.
52-week rangeUS$0.29 - US$7.45
50-day moving average US$1.7921
200-day moving average US$1.846
Target priceUS$2.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) US$-0.943

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Data updated regularly
Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro Share Trading (US stocks)
USD 0
USD 10 per month if there’s been no login for 12 months
0.50%
Forex, CFDs, US shares
Zero brokerage share trading on US stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and forex from the one account.
CMC Markets Stockbroking
USD 0
No
0.60%
ASX shares, Global shares, Forex, CFDs, Options trading, mFunds, ETFs, Warrants
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.
IG Share Trading
Finder Award
IG Share Trading
USD 0
AUD 50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares, Forex, CFDs, Margin trading
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Note: $10,000 deposit required to open account.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.
loading

Compare up to 4 providers

Is it a good time to buy iBio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

iBio financials

Revenue TTM US$2.3 million
Gross profit TTM US$1.6 million
Return on assets TTM -14.76%
Return on equity TTM -44.72%
Profit margin 0%
Book value 0.507
Market capitalisation US$425.5 million

TTM: trailing 12 months

Shorting iBio shares

There are currently 13.0 million iBio shares held short by investors – that's known as iBio's "short interest". This figure is 7.6% up from 12.0 million last month.

There are a few different ways that this level of interest in shorting iBio shares can be evaluated.

iBio's "short interest ratio" (SIR)

iBio's "short interest ratio" (SIR) is the quantity of iBio shares currently shorted divided by the average quantity of iBio shares traded daily (recently around 17.7 million). iBio's SIR currently stands at 0.73. In other words for every 100,000 iBio shares traded daily on the market, roughly 730 shares are currently held short.

However iBio's short interest can also be evaluated against the total number of iBio shares, or, against the total number of tradable iBio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case iBio's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 iBio shares in existence, roughly 60 shares are currently held short) or 0.0601% of the tradable shares (for every 100,000 tradable iBio shares, roughly 60 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against iBio.

Find out more about how you can short iBio stock.

iBio share dividends

We're not expecting iBio to pay a dividend over the next 12 months.

Have iBio's shares ever split?

iBio's shares were split on a 1:10 basis on 11 June 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your iBio shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for iBio shares which in turn could have impacted iBio's share price.

iBio share price volatility

Over the last 12 months, iBio's shares have ranged in value from as little as US$0.29 up to US$7.45. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while iBio's is -6.1478. This would suggest that iBio's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, iBio has bucked the trend.

iBio overview

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site